OpGen’s subsidiary Curetis meets milestones of extended, expanded R&D collab

OpGen reported that its German subsidiary Curetis GmbH has met all milestones under its extended and expanded research and development collaboration agreement with FIND. Following the delivery of a comprehensive milestone report at the end of the second quarter of 2023, FIND recently confirmed that all requirements have been met successfully. The extended and expanded R&D collaboration has successfully addressed the development and feasibility for an antibiotic stewardship module as part of the Unyvero A30 software suite that can be customized to guide usage of specific antibiotics based on their availability from local hospital pharmacies in relevant settings within low- and middle-income countries. Another key deliverable and milestone successfully met was the prototype of a “data everywhere” module that allows exporting the Unyvero A30 rapid antimicrobial resistance test results to mobile devices as well as into relevant cloud settings. This deliverable supports usage of Unyvero A30 test data in resource-constrained settings with minimal infrastructure as often faced in many LMICs.